Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.22
-0.11 (-0.40%)
Dec 31, 2025, 4:00 PM EST - Market closed
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
$91,785
Profits / Employee
-$822,264
Market Cap
1.59B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 488 | 102 | 26.42% |
| Dec 31, 2023 | 386 | -7 | -1.78% |
| Dec 31, 2022 | 393 | 1 | 0.26% |
| Dec 31, 2021 | 392 | -170 | -30.25% |
| Dec 31, 2020 | 562 | 26 | 4.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGIO News
- 7 days ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript - Seeking Alpha
- 7 days ago - Agios Pharma Stock: A Buy After FDA Approves Aqvesme - Seeking Alpha
- 7 days ago - Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - Invezz
- 8 days ago - Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Reuters
- 8 days ago - U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia - GlobeNewsWire
- 24 days ago - Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - GlobeNewsWire
- 6 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript - Seeking Alpha
- 6 weeks ago - Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga